A 24-month extension of a one-year, multicenter, double-blinded double dummy, randomized study to evaluate the safety and efficacy of two doses of FTY720 combined with full-dose cyclosporine, USP [Modified] (Novartis Brand) and steroids versus mycophenolate mofetil combined with full-dose cyclosporine, USP [Modified] (Novartis Brand) and steroids, in adult de novo renal transplant recipients.
Phase of Trial: Phase II
Latest Information Update: 01 Mar 2017
At a glance
- Drugs Ciclosporin; Corticosteroids; Fingolimod; Mycophenolate mofetil
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Sponsors Novartis
- 31 Aug 2018 Biomarkers information updated
- 01 Nov 2011 Actual end date (November 2006) added as reported by ClinicalTrials.gov.
- 24 Mar 2009 Primary outcomes added as reported by ClinicalTrials.gov.